Documents | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | Guidance

A list of downloadable documents created during development.

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Review proposal consultation

Stakeholder matrix 25 April 2016 35.4 KB

Review proposal paper 25 April 2016 249.49 KB

Background information

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013 24 May 2013 168.86 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document 25 March 2013 291.3 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) 25 March 2013 249.92 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products 25 March 2013 769.87 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome 25 March 2013 101.4 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer 25 March 2013 198 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing 22 March 2013 24.37 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists 25 March 2013 3.65 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO) 25 March 2013 323.89 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health 25 March 2013 22.15 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster 25 March 2013 134.51 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service 25 March 2013 314.8 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre 25 March 2013 30.24 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): comments on the ACD received from the public through the NICE website 25 March 2013 49.28 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal

Appeals received 25 March 2015 300.07 KB

Initial scrutiny letter - Pharma Mar 25 March 2015 285 KB

Response to scrutiny letter 25 March 2015 180.36 KB

Final scrutiny letter 25 March 2015 104.07 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report 23 December 2014 2.29 MB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document 23 December 2014 542.39 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report 27 September 2013 10.74 MB

Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation 22 July 2013 6.08 MB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol 18 December 2012 329.71 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM) 12 February 2013 66.58 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix 28 November 2012 66.49 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope 28 November 2012 277.58 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping 28 November 2012 28.58 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope 05 September 2012 73.98 KB

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix 05 September 2012 66.19 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): evaluation report

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing 18 December 2012 528.33 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report 18 December 2012 453.42 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check 18 December 2012 57.22 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche 18 December 2012 2.6 MB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Clarification

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter 18 December 2012 85.11 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter 18 December 2012 350.38 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Patient group, professional group and NHS organisation submission statements

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO 18 December 2012 282.23 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome 18 December 2012 107.12 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action 18 December 2012 100.14 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing 18 December 2012 6.95 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists 18 December 2012 51.56 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer 18 December 2012 91.71 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Expert written personal statements

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall 18 December 2012 38.09 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate 18 December 2012 45.13 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden 18 December 2012 45.14 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne 18 December 2012 25.51 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar 18 December 2012 51.95 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Oge Chesa 18 December 2012 40.09 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012 29 June 2012 47.37 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012 29 June 2012 129.46 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012 29 June 2012 50.55 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012 29 June 2012 55.44 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012 29 June 2012 46.25 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope 16 September 2011 46.52 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix 16 September 2011 58.14 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix 16 September 2011 38.97 KB

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope 16 September 2011 147.25 KB